Revenue
2020
2021
2022
2023
2024
2025
Oxford Biomedica plc (OXB)
Price£4.35Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | £168.7M | £128.8M | £89.5M | £140.0M | £142.8M | £87.7M |
| Gross profit | £66.0M | £53.0M | £39.7M | £69.2M | £82.6M | £46.1M |
| Gross margin | 39.10% | 41.17% | 44.37% | 49.42% | 57.87% | 52.52% |
| Research & development | £5.1M | £4.5M | £11.5M | £60.9M | £40.2M | £29.7M |
| Operating expenses | £88.5M | £92.4M | £223.9M | £99.4M | £61.9M | £51.8M |
| Operating income | −£22.5M | −£39.4M | −£184.2M | −£30.2M | £20.8M | −£5.7M |
| Operating margin | −13.32% | −30.57% | −205.69% | −21.59% | 14.54% | −6.49% |
| EBITDA | £2.4M | −£14.3M | −£148.6M | −£10.9M | — | — |
| EBITDA margin | 1.43% | −11.13% | −165.98% | −7.76% | — | — |
| Net income | −£30.6M | −£48.6M | −£184.2M | −£45.2M | £19.0M | −£6.2M |
| Net profit margin | −18.16% | −37.74% | −205.68% | −32.26% | 13.31% | −7.12% |
| Basic EPSper basic share | -£0.27 | -£0.42 | -£1.63 | -£0.41 | £0.23 | -£0.78 |
| Diluted EPSper diluted share | -£0.27 | -£0.42 | -£1.63 | -£0.41 | £0.22 | -£0.78 |